HC Wainwright Has Negative Opinion of VKTX FY2026 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX) – HC Wainwright cut their FY2026 earnings per share estimates for shares of Viking Therapeutics in a report issued on Thursday, October 29th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will earn ($5.51) per share for the year, down from their prior forecast of ($4.74). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($5.26) per share. HC Wainwright also issued estimates for Viking Therapeutics’ Q4 2026 earnings at ($1.48) EPS and FY2027 earnings at ($5.99) EPS.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported ($1.55) earnings per share for the quarter, missing the consensus estimate of ($1.06) by ($0.49). During the same quarter in the previous year, the firm earned ($0.81) earnings per share.

Other equities research analysts also recently issued reports about the stock. Oppenheimer set a $120.00 target price on shares of Viking Therapeutics in a research note on Tuesday, September 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Viking Therapeutics in a research note on Thursday, October 15th. Wall Street Zen lowered shares of Viking Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, October 4th. Morgan Stanley reissued an “overweight” rating on shares of Viking Therapeutics in a report on Tuesday, September 22nd. Finally, Truist Financial lowered their price objective on shares of Viking Therapeutics from $87.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Viking Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $93.36.

Viking Therapeutics Trading Down 1.6%

Shares of NASDAQ VKTX opened at $26.83 on Monday. The business has a 50-day moving average of $30.37 and a 200-day moving average of $32.40. The firm has a market capitalization of $3.38 billion, a price-to-earnings ratio of -4.97 and a beta of 0.66. Viking Therapeutics has a 12 month low of $23.82 and a 12 month high of $43.15.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Ameritas Advisory Services LLC purchased a new stake in shares of Viking Therapeutics during the second quarter worth about $32,000. Ballast Advisors LLC bought a new stake in shares of Viking Therapeutics in the first quarter worth about $33,000. Root Financial Partners LLC purchased a new position in Viking Therapeutics during the 3rd quarter valued at about $34,000. Allworth Financial LP purchased a new position in Viking Therapeutics during the 2nd quarter valued at about $53,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in Viking Therapeutics during the 2nd quarter valued at approximately $56,000. 76.03% of the stock is currently owned by institutional investors.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company develops therapies for metabolic and endocrine disorders, with a focus on conditions involving obesity, nonalcoholic steatohepatitis (NASH), and other liver and lipid disorders.

Viking’s lead program is VK2735, an investigational dual GLP-1/GIP receptor agonist being developed in injectable and oral formulations for obesity and related metabolic conditions.